Bmal1-Deficient Beta Cell Model for Insulin Secretion Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments are limited in effectively targeting beta cell function in insulin resistance, often leading to hypoglycemia and weight gain, and there is a need for new methods to identify drugs that enhance insulin secretion and protect beta cell survival without these complications.
Innovation Solution
Development of cells with altered cell cycle control, specifically beta cells lacking a functional Bmal1 gene, which are used in high-throughput screening to identify compounds that restore insulin secretion and oxygen consumption, employing a bioluminescent reporter gene to monitor insulin secretion and CRISPR-CAS9 gene editing to mimic clock disruption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If sulfonylureas and glinides are used to induce insulin secretion, then insulin secretion is improved, but hypoglycemia and beta cell failure progress
Solution Approach 1:
The patent employs glucose-stimulated insulin secretion as a feedback mechanism, where beta cells naturally respond to glucose levels without external drug intervention. This physiological feedback loop eliminates the hypoglycemia risk associated with sulfonylureas while maintaining effective insulin secretion during hyperglycemic states.
Solution Approach 2:
The patent extracts and targets the specific molecular pathway of glucose-stimulated insulin secretion, separating this function from the non-selective insulin secretion induction of traditional drugs. By focusing on the glucose-responsive pathway, the system achieves insulin secretion only when glucose is elevated, eliminating unnecessary secretion and hypoglycemia risk.
2Power
If GLP-1 agonists are used to stimulate insulin release, then insulin secretion is improved, but weight gain and injection requirements increase
Solution Approach 1:
The patent enables beta cells to self-regulate insulin secretion in response to glucose levels without external intervention. The endogenous glucose-stimulated insulin secretion pathway serves the system's own needs, eliminating the requirement for external injections and associated administrative burdens.
Solution Approach 2:
The patent identifies and targets intermediary molecules and signaling pathways within the beta cell that mediate glucose-stimulated insulin secretion. By activating these endogenous intermediaries, the system achieves insulin secretion without requiring external GLP-1 agonists or their associated administration systems.
3Power
If DPP4 inhibitors are used to stabilize endogenous GLP-1, then anti-hyperglycemic effects are improved, but efficacy is modest and weight gain occurs
Solution Approach 1:
The patent segments the glucose control mechanism into two independent pathways: GLP-1 mediated insulin secretion and direct glucose-stimulated insulin secretion. By activating the latter pathway through glucose-responsive beta cell mechanisms, the system achieves potent anti-hyperglycemic effects without relying on the modest efficacy of DPP4 inhibitors.
Solution Approach 2:
The patent changes the operational parameters of beta cell function by restoring and enhancing glucose-stimulated insulin secretion capacity. This parameter change transforms the system from a state of impaired secretion to one of robust, glucose-responsive insulin release, achieving superior anti-hyperglycemic effects compared to current standard therapies.
4Power
If insulin is used to treat diabetes, then blood glucose control is improved, but weight gain and hypoglycemia occur
Solution Approach 1:
The patent implements dynamic insulin secretion that automatically adjusts to glucose levels. Insulin is secreted only when glucose is elevated and stops when glucose normalizes, creating a dynamic response that prevents both hyperglycemia and hypoglycemia while avoiding the weight gain associated with continuous exogenous insulin administration.
Solution Approach 2:
The patent skips the intermediate step of exogenous insulin administration by directly activating the endogenous glucose-stimulated insulin secretion pathway. This bypasses the weight gain and hypoglycemia risks of traditional insulin therapy while maintaining effective blood glucose control through physiological mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of compounds that enhance insulin secretion and protect beta cell function, potentially leading to new diabetes treatments that avoid hypoglycemia and weight gain, while providing insights into the molecular clock's role in beta cell regulation and metabolic disorders.
Implementation Method 1
the reporter gene expresses a fluorescent or bioluminescent marker (e.g., luciferase) in response to cleavage of proinsulin
Data Source
AI summary
The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.